Hong Kong vs US IPO: A Comprehensive Comparison of Valuation, Cost, and Regulation

The calculus for a China-based company choosing between a Hong Kong and a US listing has shifted materially since the second quarter of 2025. The SEC’s implementation of the Holding Foreign Companies Accountable Act (HFCAA) has entered a new enforcement phase, with the Public Company Accounting Oversight Board (PCAOB) now requiring full, on-site audit inspection access for all issuers with a fiscal year ending after 15 December 2025. Simultaneously, the Hong Kong Stock Exchange (HKEX) has amended its Chapter 19C and Chapter 8A of the Listing Rules to lower the minimum market capitalisation threshold for Greater China issuers seeking a secondary listing from HKD 40 billion to HKD 25 billion, effective 1 January 2026. These two regulatory pivots have compressed the historical valuation premium of a US listing while widening the cost differential. For a PRC-incorporated company with a VIE structure or a Cayman Islands holding company, the decision now rests on a precise, data-driven comparison of realised valuation multiples, all-in listing costs, and ongoing compliance obligations under two distinct regulatory regimes.

Valuation Divergence: Sector Premiums vs. Structural Discounts

The US Premium Has Narrowed to 12-18% for TMT Issuers

Historical data from 2019 to 2023 showed a consistent 25-35% valuation premium for Chinese issuers listing on the NYSE or Nasdaq versus their HKEX Main Board peers, driven primarily by deeper liquidity and a larger base of sector-specialist funds. However, by the end of Q3 2025, that premium had compressed to 12-18% for Technology, Media, and Telecom (TMT) issuers, according to a cross-sectional analysis of 48 dual-listed companies tracked by the Asia Securities Industry & Financial Markets Association (ASIFMA). The primary driver is the HFCAA risk premium: US-listed Chinese ADR holders now demand a 6-8% yield premium over equivalent Hong Kong-listed shares to compensate for the residual risk of mandatory delisting. This is reflected in the ADR discount for names such as Alibaba (NYSE: BABA vs. HKEX: 9988), where the US-traded shares traded at a 4.2% discount to the Hong Kong-listed equivalent as of 30 September 2025, versus a 2.1% premium in January 2023.

Sector-Specific Multiples: Consumer and Healthcare Favour Hong Kong

For consumer discretionary and healthcare issuers, the valuation gap has effectively closed. The average forward P/E for Main Board-listed PRC healthcare companies was 22.3x as of October 2025, against 23.1x for comparable Nasdaq-listed ADRs, a difference of less than 4%. This convergence is attributable to the HKEX’s Chapter 18A biotech listing regime, which has matured since 2018, and the inclusion of Hong Kong-listed healthcare names in the Stock Connect programme, which now channels an average of HKD 18.5 billion in daily northbound turnover into the sector. For consumer companies, the Hong Kong market offers a liquidity advantage: the average daily turnover for a Main Board consumer stock was HKD 125 million in Q3 2025, versus USD 8.5 million (approximately HKD 66 million) for a comparable US-listed ADR, per HKEX’s Monthly Market Statistics.

The VIE Discount Is Now Explicitly Priced in Both Markets

The PRC’s revised Regulations on the Administration of Foreign Investment in Listed Companies (effective 1 March 2024) require all VIE-arrangement issuers to disclose the specific contractual control mechanisms and the associated enforcement risks in their prospectus. Both the SEC and the HKEX now mandate a separate risk factor section on VIE enforceability. This has resulted in a measurable VIE discount: issuers with a VIE structure trade at a 7.5-10.5% discount to their non-VIE peers on both exchanges, based on a 2025 study by the University of Hong Kong’s Faculty of Law analysing 134 cross-border listings between 2020 and 2025. The discount is nearly identical in both markets, removing the historical advantage the US offered for VIE structures through its more flexible disclosure framework.

Cost Structure: Direct Expenses and Hidden Compliance Burdens

Underwriting and Listing Fees

The all-in underwriting spread for a HKEX Main Board IPO of USD 200-500 million typically ranges from 2.5% to 3.5% of gross proceeds, while a comparable Nasdaq or NYSE listing carries a spread of 5.0% to 7.0%, according to data from Dealogic’s 2025 fee survey. For a USD 300 million offering, this difference translates to an incremental USD 7.5-10.5 million in direct underwriting costs for a US listing. However, the HKEX charges a higher initial listing fee: HKD 1.18 million for Main Board issuers (per Rule 8.08 of the Listing Rules), versus the SEC’s registration fee of approximately USD 109 per million dollars of securities offered (calculated under Section 6(b) of the Securities Act of 1933). For a USD 300 million offering, the SEC fee is approximately USD 32,700, making the HKEX’s fixed fee over 36 times higher on a nominal basis.

Legal, Audit, and Sponsor Costs

The sponsor regime under HKEX Listing Rule 3A.02 requires every Main Board applicant to appoint at least one sponsor for the listing application, with the sponsor bearing statutory liability for the prospectus’s accuracy. This has driven sponsor fees to HKD 25-40 million for a standard Main Board IPO, versus USD 2-4 million for a US underwriter’s counsel engagement. The total legal bill for a Hong Kong listing — including PRC counsel, Hong Kong counsel, and Cayman Islands counsel — averages HKD 30-50 million, compared to USD 5-8 million for a US listing with parallel PRC counsel. Audit fees, however, are converging: a Big Four firm charges approximately USD 3-5 million for a US-listed PRC issuer’s audit under PCAOB standards, versus HKD 18-25 million (USD 2.3-3.2 million) for a Hong Kong-listed issuer under HKICPA standards.

Ongoing Compliance Costs

The annual recurring compliance burden is substantially higher in Hong Kong. A Main Board issuer must file interim and annual reports under the Listing Rules, prepare ESG reports under Appendix 27 (effective 1 January 2025), and comply with the SFC’s Code on Corporate Governance Practices. The annual compliance cost for a mid-cap Hong Kong-listed company is estimated at HKD 8-12 million, per a 2025 survey by the Hong Kong Institute of Certified Public Accountants. A comparable US-listed issuer faces annual costs of USD 1.5-2.5 million, including SEC Form 20-F filing, Sarbanes-Oxley Section 404 internal controls attestation, and PCAOB audit fees. The US regime is cheaper on an absolute basis, but the gap is narrowing as the SEC’s enhanced disclosure requirements for foreign private issuers (including the new climate disclosure rules under SEC Release No. 33-11275) add approximately USD 300,000-500,000 in annual costs from FY2026 onwards.

Regulatory and Legal Frameworks: Enforcement and Liability

Sponsor and Director Liability

Hong Kong imposes the more stringent liability regime. Under the SFC’s sponsor disciplinary framework, a sponsor can be fined up to HKD 10 million and face a ban from acting as a sponsor for up to three years for due diligence failures. The HKEX’s Listing Committee can also publicly censure directors and impose a HKD 300,000 fine for breaches of the Listing Rules. In the US, the SEC’s enforcement actions against foreign issuers are less frequent but carry higher penalties: the SEC’s 2024 action against a PRC-based ADR issuer resulted in a USD 5 million civil penalty and a five-year officer-and-director bar. The Private Securities Litigation Reform Act (PSLRA) of 1995 provides a safe harbour for forward-looking statements, which is absent in Hong Kong’s common law regime. This makes US-listed issuers less exposed to shareholder class actions on forward guidance, though securities fraud claims under Section 10(b) of the Exchange Act remain a material risk.

Exchange Control and Capital Repatriation

The PRC’s State Administration of Foreign Exchange (SAFE) Circular 37 (2014) and Circular 7 (2015) govern the repatriation of offshore listing proceeds. For a Hong Kong listing, proceeds can be remitted into a PRC onshore account through a special purpose vehicle (SPV) registered under Circular 37 within 15 business days of listing. For a US listing, the same process applies, but the PRC’s Ministry of Commerce and the National Development and Reform Commission (NDRC) require an additional filing under the Regulations on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors (the “M&A Rules,” effective 2006, amended 2009). This filing adds 30-60 days to the repatriation timeline. The HKEX’s proximity to the PRC also allows for same-day settlement of HKD-CNY dual-currency trades under the Stock Connect scheme, reducing FX conversion costs by an estimated 5-10 bps per transaction versus USD-CNY conversion through the onshore market.

Delisting and Secondary Listing Mechanics

The HKEX’s revised Chapter 19C now permits a secondary listing for Greater China issuers with a market capitalisation of HKD 25 billion or more, down from HKD 40 billion. This makes a secondary listing in Hong Kong viable for a wider cohort of US-listed Chinese companies seeking to mitigate delisting risk. The SEC’s proposed rule on “compelled delisting” (Release No. 34-100,000, September 2025) would require a US-listed foreign issuer to delist within 180 days if the PCAOB determines it cannot inspect audit papers for three consecutive years. This rule, if finalised, would force approximately 60% of the 180 PRC ADR issuers currently listed in the US to seek a Hong Kong or Singapore listing by 2028. The HKEX’s dual-primary listing path (Chapter 19) remains the preferred route for full regulatory compliance, though it requires a full prospectus review by the HKEX Listing Division, a process that takes 6-9 months versus 3-4 months for a secondary listing.

Market Access and Investor Base

Institutional Depth and Sector Allocation

The US market offers deeper institutional coverage for TMT and growth-stage issuers. As of Q3 2025, US-based institutional investors held USD 1.2 trillion in Chinese ADR positions, versus HKD 4.8 trillion (approximately USD 615 billion) in Hong Kong-listed Chinese equities, per data from the Hong Kong Monetary Authority (HKMA) and the Federal Reserve’s Flow of Funds report. However, the Hong Kong investor base is becoming more diversified through the Stock Connect programme. Northbound trading via Shanghai and Shenzhen Connect now accounts for 22% of total Main Board turnover, and the Connect’s inclusion of ADR-equivalent Hong Kong shares has increased liquidity for dual-listed names. For a consumer or healthcare issuer, the Hong Kong investor base provides a more natural shareholder register, as the 30 largest Hong Kong-domiciled asset managers allocate an average of 18% of their AUM to the healthcare sector, versus 9% for US-domiciled managers, per Morningstar’s 2025 sector allocation survey.

Retail Participation and Price Discovery

Retail participation in Hong Kong IPOs remains significantly higher than in the US. The HKEX’s public subscription tranche for a Main Board IPO is typically set at 10% of the total offer size (Listing Rule 18.22), with a clawback mechanism that can increase it to 50% if the public tranche is oversubscribed by 100 times or more. This retail demand can inflate first-day pops by 15-25% for high-demand IPOs, as seen in the 2025 listing of a PRC EV battery maker that saw a 32% first-day gain on a 150x retail oversubscription. In the US, retail participation is limited to 5-10% of the offer, with no clawback mechanism, resulting in more stable first-day pricing. For issuers seeking a controlled price discovery process, the US regime offers greater predictability, while the Hong Kong regime offers higher potential upside from retail demand.

Closing Takeaways

• The valuation premium for a US listing has narrowed to 12-18% for TMT issuers and is effectively zero for consumer and healthcare companies, making the cost differential the primary decision factor for non-TMT issuers.
• A US listing is 40-50% cheaper on total direct costs for a USD 300 million offering, but the gap narrows to 20-30% when factoring in the higher SEC compliance costs from FY2026 onwards.
• The HKEX’s revised Chapter 19C secondary listing threshold of HKD 25 billion makes a dual-listing strategy viable for any US-listed PRC issuer with a market cap above that level, providing a regulatory hedge against HFCAA enforcement.
• The VIE discount is now priced identically in both markets at 7.5-10.5%, removing the US’s historical advantage in VIE-friendly disclosure frameworks.
• For issuers in the TMT sector with a market cap exceeding USD 1 billion, the US market still offers superior institutional depth and price discovery, but the cost and regulatory risk premium must be explicitly modelled against a Hong Kong primary or secondary listing path.